FDA stiff arms Evolus' rival to Allergan’s blockbuster Botox, but execs promise a snap response
Evolus’ $EOLS attempt to field a rival to Allergan’s Botox has run into problems at the FDA.
The biotech announced Wednesday morning that the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
